TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman

Telix Pharmaceuticals is facing a securities class action lawsuit after revealing an SEC investigation into its prostate cancer therapeutic candidates and receiving an FDA Complete Response Letter for its Zircaix drug, which caused significant stock price decline.

Insights
TLX   negative

Company faced SEC investigation, FDA rejection, potential misleading statements to investors, and significant stock price drop during the class period of February to August 2025